5 Minutes Read
AstraZeneca begins worldwide withdrawal of COVID-19 vaccine
KV Prasad Jun 13, 2022, 06:35 AM IST (Published)
Listen to the Article (6 Minutes)
Summary
Media reports said that the company has admitted in court documents that the vaccine causes side-effects such as blood clots, low blood platelet counts and “in very rare cases, cause TTS or Thrombosis with Thrombocytopenia Syndrome”.
AstraZeneca has initiated the worldwide withdrawal of its COVID-19 vaccine Vaxzevria due to a “surplus of available updated vaccines” which has led to a decline in its demand.
“As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company told Telegraph. The vaccine is neither being manufactured nor supplied.
The report said that the firm’s application to withdraw the vaccine was made on March 5 and came into effect on May 7. The report said the vaccine cannot be used in the European Union after the company withdrew its “marketing authorisation”.
Media reports said that the company has admitted in court documents that the vaccine causes side-effects such as blood clots, low blood platelet counts and “in very rare cases, cause TTS or Thrombosis with Thrombocytopenia Syndrome”. The company is being sued by more than 50 alleged victims and relatives in a High Court case.
The drugmaker faces a £100 million lawsuit in the UK over claims that the Covid jab caused deaths and injuries to several people.
Without referring to the side effects, the company said, “we are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. It added, “Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic.”
In India, over 220 crore dosages of COVID-19 vaccines have been administered and a majority of those were Covishield.
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter
Daily Newsletter
